Page last updated: 2024-12-04

oxyquinoline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Oxyquinoline: An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

quinolin-8-ol : A monohydroxyquinoline that is quinoline substituted by a hydroxy group at position 8. Its fungicidal properties are used for the control of grey mould on vines and tomatoes. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1923
CHEMBL ID310555
CHEBI ID48981
SCHEMBL ID37189
MeSH IDM0023266

Synonyms (206)

Synonym
nsc-48037
nsc-82405
nsc-82410
nsc-82404
nsc-54230
nsc-82412
nsc-82409
BIDD:ER0371
j2.960b ,
CHEMBL310555 ,
EN300-17403
BRD-K66808046-065-01-1
albisal
nsc-615011
8-oxyquinoline
oxychinolin
bioquin
usaf ek-794
nci-c55298
phenopyridine
oxyquinoline
148-24-3
oxin
wln: t66 bnj jq
1-azanaphthalene-8-ol
8-quinol
oxybenzopyridine
oxine
nsc2039
8-oq
tumex
8-hydroxychinolin
8-hydroxyquinoline ,
fennosan h 30
quinophenol
8-quinolinol
hydroxybenzopyridine
nsc-2039
NSC285166 ,
nsc 285166
nsc 82410
oxoquinoline
nsc 615011
nsc 82404
nsc 54230
KBIO1_000757
DIVK1C_000757
NCIOPEN2_001220
NCI60_001712
NCIOPEN2_001020
NCI60_002335
NCIMECH_000694
NCIOPEN2_000962
MLS001055492
smr000112313
SPECTRUM_001053
manganese, bis(8-quinolinolato)-
nsc615011
mls002702126 ,
nsc-285166
oxyquinoline (usan)
D05321
BSPBIO_002147
quinolin-8-ol
inchi=1/c9h7no/c11-8-5-1-3-7-4-2-6-10-9(7)8/h1-6,11
nsc-402623
nsc402623
AP-065/40180076
NCGC00090708-01
NCGC00090708-02
8-hydroxy-chinolin
CHEBI:48981 ,
8-chinolinol
brn 0114512
fennosan hf-15
epa pesticide chemical code 059803
ccris 340
oxyquinoline [usan]
o-oxychinolin [german]
ai3-00483
hydroxyquinoline
quinoline, 8-hydroxy-
fennosan
einecs 205-711-1
8-hydroxy-chinolin [german]
8-chinolinol [czech]
hsdb 4073
caswell no. 719
8-hydroxyquinoline, crystalline
CU-01000012874-2
8-hydroxyquinoline, acs reagent, 99%
NCGC00090708-03
nsc 2039
nsc 402623
nsc 82409
8-quinolinol (7ci,8ci,9ci)
nsc 48037
nsc 82412
nsc 82405
KBIO2_006669
KBIOSS_001533
KBIO2_001533
KBIO2_004101
KBIOGR_000910
KBIO3_001647
SPBIO_000853
SPECTRUM4_000465
NCISTRUC2_000240
NCIOPEN2_004264
NINDS_000757
NCISTRUC1_000152
SPECTRUM2_000697
SPECTRUM3_000534
IDI1_000757
SPECTRUM5_001280
NCGC00090708-04
8 oxyquinoline
oxyquinol
8 hydroxyquinoline
8 quinolinol
8-quinolinol, >=99% (perchloric acid titration)
8-quinolinol, puriss. p.a., acs reagent, reag. ph. eur., >=99% (perchloric acid titration)
hqy ,
AC-5109
AKOS001061311
HMS502F19
H0305
8-quinolinone
A808745
NCGC00090708-06
NCGC00090708-07
NCGC00090708-05
NCGC00090708-08
C19434
dtxcid30730
cas-148-24-3
tox21_400006
dtxsid5020730 ,
NCGC00260531-01
tox21_202986
tox21_113083
8-hydroxy quinoline
8-oxychinolin
o-oxychinolin
S4547
STK943764
CCG-35870
5utx5635hp ,
5-21-03-00252 (beilstein handbook reference)
unii-5utx5635hp
ec 205-711-1
FT-0621550
AM20050821
oxyquinoline [ii]
8-hydroxyquinoline [mi]
hydroxyquinoline [who-dd]
oxyquinoline [hsdb]
oxyquinoline [inci]
hydroxyquinoline [vandf]
oxyquinoline [vandf]
8-hydroxyquinoline [iarc]
SCHEMBL37189
3VH9
8-hydroxy-quinoline
CS-4502
PS-4553
8-hydroxychinoline
8-hydroxiquinoline
8-quinolol
oxychinoline
8-oxyquinolin
W-108106
us9394254, 6
bdbm32203
cid_1923
STR00721
HY-B1005
AB00052065_08
mfcd00006807
F0001-0526
8-quinolinol, jis special grade, >=99.0%
8-quinolinol, pestanal(r), analytical standard
8-quinolinol, puriss. p.a., acs reagent, for the detection and determination of al, mg and others, >=99.0% (nt)
8-hydroxyquinoline, 99%
P17615
8-quinolinol, vetec(tm) reagent grade, 99%
8-quinolinol, p.a.
oxyquinoline (8-hydroxyquinoline)
SBI-0051472.P003
Z56926518
8-hydroxyquinoline acs reagent grade
oxine;8-hydroxyquinoline;quinophenol;8-quinolinone
DB11145
quinoline-8-ol
Q270162
8-hydroxyquinoline acs grade 100g
NCGC00090708-11
8-hydroxylquinoline
8-hydroxyquinoline oxine
SB40773
oxyquinol reference spectrum
8-oxychinolin, 8-quinolinol, oxine
pesticide code: 059803
oxyquinoline (ii)
udder balm
8-hydroxyquinoline (iarc)

Research Excerpts

Overview

Oxyquinoline is a heterocyclic phenol and Oxyquinoline Sulfate is its salt. Both are described as cosmetic biocides for use in cosmetic formulations.

ExcerptReferenceRelevance
"Oxyquinoline is a heterocyclic phenol and Oxyquinoline Sulfate is its salt, both of which are described as cosmetic biocides for use in cosmetic formulations. "( Final amended report on the safety assessment of oxyquinoline and oxyquinoline sulfate as used in cosmetics.
Andersen, A, 2006
)
2.03

Actions

ExcerptReferenceRelevance
"Oxyquinoline derivatives suppress activity of HIF-prolyl hydroxylases leading to HIF activation in the cell."( Oxyquinoline-Dependent Changes in Claudin-Encoding Genes Contribute to Impairment of the Barrier Function of the Trophoblast Monolayer.
Gazizov, IN; Gerasimenko, TN; Knyazev, EN; Petrov, VA; Sukhikh, GT; Tonevitsky, AG; Tsypina, IM, 2019
)
2.68

Treatment

ExcerptReferenceRelevance
"Hydroxyquinoline-treated soil had lower values for the CO(2) release compared to untreated non-sterile soil."( Interaction of 8-hydroxyquinoline with soil environment mediates its ecological function.
Bajpai, D; Rajeswari, MS, 2010
)
1.16

Toxicity

ExcerptReferenceRelevance
" Adverse effects were mild and did not affect treatment."( A study on the neurotoxicity of broxyquinoline and brobenzoxaldine combination in therapeutic doses.
Bapna, JS; Bosco, B; Chandrasekar, S; Das, AK; Swain, R; Swaminathan, RP; Thombre, DP; Veliath, S, 1986
)
0.55
"The preparation is given of an 111indium-oxine complex that is non toxic and can label reproductively various types of cells."( Measurements of cell-mediated cytotoxicity on target cells labelled with the indium-111-oxine complex.
Czichosz, R; Firket, H; Guillaume, M; Schaaf-Lafontaine, N; Smet-Donnay, M, 1985
)
0.27
"While oxine-copper (OxCu) is generally used as an agricultural fungicide and induces a harmful effect on ecosystems, little information is available regarding a toxic effect of OxCu on mammals."( [In vivo toxicity, lipid peroxide lowering, and glutathione, ascorbic acid and copper elevation induced in mouse liver by low dose of oxine-copper, a fungicide].
Hashimoto, I; Hojo, Y; Kawazoe, S; Miyamoto, Y; Mizutani, T, 2000
)
0.31
" The available data demonstrate that Oxyquinoline and Oxyquinoline Sulfate are safe as stabilizers for hydrogen peroxide in rinse-off hair care cosmetic products in the present practices of use."( Final amended report on the safety assessment of oxyquinoline and oxyquinoline sulfate as used in cosmetics.
Andersen, A, 2006
)
0.86
"Cytotoxic effects of In on human stem cells is a time-dependent phenomenon and hence, assessment of the stem cell viability immediately after labeling (which is frequently made in clinical trials) is unable to detect adverse effects of this radiopharmaceutical on the integrity of stem cells."( Cytotoxicity of 111In-oxine on mesenchymal stem cells: a time-dependent adverse effect.
Alimoghadam, K; Ardekani, JM; Bagheri, M; Gholamrezanezhad, A; Malekzadeh, R; Mirpour, S; Yarmand, S, 2009
)
0.35
" These results suggested that 8-HOQ is potentially harmful to fish and may be a toxic contaminant in the aquatic environment."( Genotoxic effects of 8-hydroxylquinoline in loach (Misgurnus anguillicaudatus) assessed by the micronucleus test, comet assay and RAPD analysis.
Chang, ZJ; Chen, JJ; Du, QY; Nan, P; Wu, XH; Xia, XH, 2013
)
0.39
" These data suggest that 8-HOQ may be toxic to the health of aquatic organisms when accidentally released into aquatic ecosystems."( Toxicity of 8-Hydroxyquinoline in Cryprinus carpio Using the Acute Toxicity Test, Hepatase Activity Analysis and the Comet Assay.
Chang, Z; Chen, L; Dou, X; Du, Q; He, Q; Nan, M; Nan, P; Qi, M; Yan, S, 2015
)
0.75
"The described complex methodological approach could serve as a simple yet precise tool for evaluating novel, effective and safe cobalt chelators."( A Complex Methodological Approach for the Screening of Efficient and Safe Cobalt Chelators.
Argento, R; Catapano, MC; Hrubša, M; Jirkovský, E; Kučera, R; Lomozová, Z; Mercolini, L; Mladěnka, P; Moravcová, M, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" Coating nanoparticles with polymers such as chitosan greatly affects their pharmacokinetic behavior, stability, tissue uptake, and controlled drug delivery."( Pharmacokinetic Evaluation of
Akbari, J; Gharibkandi, NA; Hosseinimehr, SJ; Molavipordanjani, S, 2019
)
0.51

Compound-Compound Interactions

ExcerptReferenceRelevance
" 8Q showed some antitumor activity alone but had much better therapeutic effect and relapse prevention when combined with paclitaxel than either 8Q or paclitaxel alone in both MCF7 and MDA-MB-435 xenograft models."( Cancer stem/progenitor cell active compound 8-quinolinol in combination with paclitaxel achieves an improved cure of breast cancer in the mouse model.
Gu, P; Margolick, JB; Yin, D; Zhang, H; Zhang, Y; Zhou, J, 2009
)
0.35

Bioavailability

ExcerptReferenceRelevance
" But the higher bioavailability of zinc in human milk should not only be attributed to the presence of citrate."( [Effect of different concentrations of various zinc complexes (picolinate, citrate, 8-hydroxyquinolate) in comparison with sulfate on zinc supply status in rats].
Kirchgessner, M; Roth, HP, 1983
)
0.27
" Tris(8-quinolinolato)Ga (III) could be as effective as transferrin-Ga, but with the advantage of oral administration and a greater bioavailability of the tris(8-quinolinolato)Ga (III) compound."( Inhibitory effects of gallium chloride and tris (8-quinolinolato) gallium III on A549 human malignant cell line.
Cazabat, A; Collery, P; Evangelou, A; Juvin, E; Keppler, B; Khassanova, L; Lechenault, F,
)
0.13
" With the aim of improving the disappointingly low activity of inorganic gallium salts, we have developed the orally bioavailable gallium complex KP46 [tris(8-quinolinolato)gallium(III)] that had already been successfully studied in a phase I clinical trial."( The gallium complex KP46 exerts strong activity against primary explanted melanoma cells and induces apoptosis in melanoma cell lines.
Berger, W; Heffeter, P; Jakupec, MA; Keppler, BK; Marculescu, R; Rappersberger, K; Valiahdi, SM, 2009
)
0.35
" A steady interest of drug developers and clinicians in gallium compounds is due to a proven ability of gallium cations to inhibit tumour growth, on the one hand, and enhanced bioavailability and moderate toxicity provided by the conversion of gallium into chelate complexes, on the other."( Advances in developing tris(8-quinolinolato)gallium(iii) as an anticancer drug: critical appraisal and prospects.
Timerbaev, AR, 2009
)
0.35
" It was found that used glycoconjugation strategy influenced both improvement of activity and improvement of the bioavailability of 8-HQ derivatives."( Synthesis of 8-hydroxyquinoline glycoconjugates and preliminary assay of their β1,4-GalT inhibitory and anti-cancer properties.
Krawczyk, M; Kuczak, M; Mrozek-Wilczkiewicz, A; Musiol, R; Pastuch-Gawolek, G; Skonieczna, M, 2019
)
0.84
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The use of materials with high biocompatibility as drug delivery carriers for metal-organic complexes to enhance the bioavailability of the drug is a feasible approach."( Gallium Metal-Organic Nanoparticles with Albumin-Stabilized and Loaded Graphene for Enhanced Delivery to HCT116 Cells.
Li, Z; Liao, WH; Niu, ZL; Wu, TT; Wu, YY; Xie, MJ; Xu, JY; Zhao, QH; Zhou, SH, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" Quinoline did, however, induce a potent mitogenic response in the rat liver between 24 and 48 hr after oral dosing of 200-500 mg/kg."( Quinoline: unscheduled DNA synthesis and mitogenesis data from the rat liver in vivo.
Ashby, J; Bandara, L; Lefevre, PA; Mohammed, R, 1989
)
0.28
" Platelet accumulation at the PTA site occurred with both doses of aspirin, with no differences between the two dosage groups."( Platelet deposition at angioplasty sites and its relation to restenosis in human iliac and femoropopliteal arteries.
Ahmadi, R; Dudczak, R; Ehringer, H; Jung, M; Koppensteiner, R; Leitha, T; Minar, E; Stümpflen, A, 1989
)
0.28
" There was no ideal "gold standard" to which our imaging results could be compared, but we used a combination of biopsy findings, clinical impressions, and changes in renal function after pulsing with steroids and/or decreasing CYS dosage as the basis for our diagnoses."( Evaluation of the utility of indium-111 oxine platelet imaging in renal transplant patients on cyclosporine.
Darcourt, J; Koyle, MA; Marcus, CS; Vivian, M, 1986
)
0.27
" The use of 99Tcm is scintigraphically more advantageous and, with the dosage required, the absorbed radiation dose to the red bone marrow is three times lower than with 111In granulocytes."( 99Tcm-labelled HSA-nanocolloid versus 111In oxine-labelled granulocytes in detecting skeletal septic process.
de Schrijver, M; Fridrich, R; Streule, K, 1988
)
0.27
" Dose-response curves were generated using such proinflammatory materials as formyl-methionyl-leucyl-phenylalanine, lipopolysaccharide, activated serum, trypsin, glycogen, and acetic acid."( Labeling of peripheral blood polymorphonuclear leukocytes with indium-111: a new method for the quantitation of in-vivo accumulation of PMNLs in rabbit skin.
Barnes, B; Lazarus, GS; Wahba, AV, 1984
)
0.27
" Meanwhile, the tailing length of comet DNA is related to the increasing dosage of CuQ."( Role of reactive oxygen species in cupric 8-quinolinoxide-induced genotoxic effect.
Kuo, ML; Wang, YH; You, BY, 2001
)
0.31
" The proposed method was successfully applied for the analysis of the studied drugs in single or combined dosage forms with average% recoveries of 99."( LC of pharmaceutically important halogenated 8-hydroxyquinolines after precolumn derivatization with Pd (II).
Ahmed, S; Belal, F; Ibrahim, F; Rizk, M; Sheribah, ZA, 2002
)
0.57
" Associations between the specific activity and radiotracer dosage was significant (P=0."( Cytotoxicity of 111In-oxine on mesenchymal stem cells: a time-dependent adverse effect.
Alimoghadam, K; Ardekani, JM; Bagheri, M; Gholamrezanezhad, A; Malekzadeh, R; Mirpour, S; Yarmand, S, 2009
)
0.35
"8, but display excellent solubility at low pH, suggesting that oral dosing may be possible."( Identification of clinically viable quinolinol inhibitors of botulinum neurotoxin A light chain.
Barlow, DJ; Benoni, G; Bompiani, KM; Caglič, D; Dickerson, TJ; Houseknecht, KL; Krutein, MC; Lairson, LL; Pelletier, JC; Reitz, AB; Smith, GR, 2014
)
0.4
" The influences of the dosage of emulsifier, porogen and outer aqueous phase on the morphology and adsorption property of MIP were studied."( [Synthesis and adsorption property of Cd(II) - 8-hydroxyquinoline molecularly imprinted polymer microspheres].
Chang, ZQ; Chen, FB; Yang, CY; Zhang, ZJ; Zhao, H, 2014
)
0.65
" The immune response developed was evaluated by the production of IFN-γ, IL-4, IL-10, IL-12 and GM-CSF cytokines, as well as by antileishmanial nitrite dosage and antibodies production."( Treatment of murine visceral leishmaniasis using an 8-hydroxyquinoline-containing polymeric micelle system.
Alves, RJ; Barichello, JM; Carvalho, AM; Coelho, EA; Duarte, MC; Lage, DP; Lage, LM; Martins, VT; Menezes-Souza, D; Roatt, BM; Tavares, CA, 2016
)
0.68
" The described method was successfully applied to the determination of molnupiravir in pure form and in pharmaceutical dosage form."( Green adherent spectrophotometric determination of molnupiravir based on computational calculations; application to a recently FDA-approved pharmaceutical dosage form.
Abd Elhalim, LM; Abdelazim, AH; Abourehab, MAS; Almrasy, AA; Ramzy, S, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antibacterial agentA substance (or active part thereof) that kills or slows the growth of bacteria.
iron chelatornull
antiseptic drugA substance used locally on humans and other animals to destroy harmful microorganisms or to inhibit their activity (cf. disinfectants, which destroy microorganisms found on non-living objects, and antibiotics, which can be transported through the lymphatic system to destroy bacteria within the body).
antifungal agrochemicalAny substance used in acriculture, horticulture, forestry, etc. for its fungicidal properties.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
monohydroxyquinolineA hydroxyquinoline carrying a single hydroxy substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (9)

PathwayProteinsCompounds
morphine biosynthesis234
morphine biosynthesis536
1,4-dichlorobenzene degradation919
aromatic biogenic amine degradation (bacteria)335
naphthalene degradation (aerobic)929
superpathway of aromatic compound degradation via 2-hydroxypentadienoate5095
naphthalene degradation to acetyl-CoA1138
ammonia oxidation I (aerobic)924
flaviolin dimer and mompain biosynthesis622
glycerol degradation V416

Protein Targets (77)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency31.62280.140911.194039.8107AID2451
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency22.38720.631035.7641100.0000AID504339
LuciferasePhotinus pyralis (common eastern firefly)Potency70.97990.007215.758889.3584AID1224835
interleukin 8Homo sapiens (human)Potency59.55720.047349.480674.9780AID651758
acetylcholinesteraseHomo sapiens (human)Potency35.80620.002541.796015,848.9004AID1347395; AID1347398
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency1.67933.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency1.09760.006038.004119,952.5996AID1159521; AID1159523
ATAD5 protein, partialHomo sapiens (human)Potency25.91850.004110.890331.5287AID504467
Fumarate hydrataseHomo sapiens (human)Potency14.12540.00308.794948.0869AID1347053
GALC proteinHomo sapiens (human)Potency1.584928.183828.183828.1838AID1159614
GLS proteinHomo sapiens (human)Potency28.18380.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency6.64710.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency0.37880.000714.592883.7951AID1259368; AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency9.66840.000221.22318,912.5098AID1259243; AID1259247; AID588515; AID588516; AID743035; AID743042; AID743054; AID743063
Smad3Homo sapiens (human)Potency3.54810.00527.809829.0929AID588855
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency31.69740.013326.981070.7614AID1346978
thyroid stimulating hormone receptorHomo sapiens (human)Potency29.88160.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency6.55460.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency4.39750.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency15.21760.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency2.82580.01237.983543.2770AID1645841
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency11.22020.28189.721235.4813AID2326
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency12.67480.000214.376460.0339AID720691; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency0.21900.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency1.25530.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency15.47320.001530.607315,848.9004AID1224819; AID1224820; AID1224821; AID1224823; AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency4.84610.375827.485161.6524AID743217; AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency1.15650.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency15.98180.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075; AID743077; AID743078; AID743079
polyproteinZika virusPotency14.12540.00308.794948.0869AID1347053
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency10.00000.707936.904389.1251AID504333
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency0.72580.001024.504861.6448AID743212; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency27.16320.001019.414170.9645AID743094; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency2.43430.023723.228263.5986AID743222; AID743223; AID743241
caspase-3Homo sapiens (human)Potency31.69740.013326.981070.7614AID1346978
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.14130.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency19.33120.000723.06741,258.9301AID743085
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency6.78410.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency0.61130.001628.015177.1139AID1224843
activating transcription factor 6Homo sapiens (human)Potency0.11480.143427.612159.8106AID1159516
thyrotropin-releasing hormone receptorHomo sapiens (human)Potency4.91570.154917.870243.6557AID1346877
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency1.662719.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency0.40270.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency2.32690.039147.5451146.8240AID1224845; AID1224896
Caspase-7Cricetulus griseus (Chinese hamster)Potency2.18000.006723.496068.5896AID1346980
caspase-3Cricetulus griseus (Chinese hamster)Potency2.18000.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency6.82280.000323.4451159.6830AID743065; AID743066; AID743067
heat shock protein beta-1Homo sapiens (human)Potency0.38560.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency33.83870.000627.21521,122.0200AID651741; AID720636; AID743202; AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency2.06100.00798.23321,122.0200AID2546; AID2551
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)Potency6.30960.058010.694926.6086AID602310
lethal factor (plasmid)Bacillus anthracis str. A2012Potency1.00000.020010.786931.6228AID912
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency0.95590.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency21.96700.002319.595674.0614AID651631; AID720552
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency0.95590.001551.739315,848.9004AID1259244
Alpha-synucleinHomo sapiens (human)Potency25.11890.56239.398525.1189AID652106
Nuclear receptor ROR-gammaHomo sapiens (human)Potency3.34910.026622.448266.8242AID651802
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency2.81840.009610.525035.4813AID1479145
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency68.58960.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency68.58960.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Bacterial leucyl aminopeptidaseVibrio proteolyticusKi0.58000.58000.58000.5800AID977610
90-kda heat shock protein beta HSP90 beta, partialHomo sapiens (human)IC50 (µMol)50.00000.17369.803229.2701AID712
heat shock protein HSP 90-alpha isoform 2Homo sapiens (human)IC50 (µMol)50.00000.17369.803229.2701AID712
26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)IC50 (µMol)100.00000.00701.09812.5000AID1480589
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
ThermolysinBacillus thermoproteolyticusIC50 (µMol)350.00000.00301.93259.5000AID346257
ThermolysinBacillus thermoproteolyticusKi214.00000.01151.14192.2909AID346257
CholinesteraseHomo sapiens (human)IC50 (µMol)0.10000.00001.559910.0000AID491973
72 kDa type IV collagenaseHomo sapiens (human)IC50 (µMol)130.00000.00001.284810.0000AID566708
Botulinum neurotoxin type A Clostridium botulinumIC50 (µMol)16.95000.50003.16927.2000AID1068575; AID1434686
Indoleamine 2,3-dioxygenase 1Homo sapiens (human)IC50 (µMol)750.00000.05373.075710.0000AID443993
Catechol O-methyltransferaseHomo sapiens (human)IC50 (µMol)2.37360.00101.31466.3096AID1363208; AID1363242
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)0.10000.00000.933210.0000AID491974
Catechol O-methyltransferaseRattus norvegicus (Norway rat)IC50 (µMol)21.37960.00222.81277.0795AID1149251
Methionine aminopeptidase 2Homo sapiens (human)IC50 (µMol)2.96670.00060.96835.6000AID1339157; AID489476; AID760045
Methionine aminopeptidase 1Homo sapiens (human)IC50 (µMol)16.46678.10008.10008.1000AID1339156; AID489474; AID760046
Glutaminyl-peptide cyclotransferaseHomo sapiens (human)IC50 (µMol)208.00005.00005.00005.0000AID1893771
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histone deacetylase 8Homo sapiens (human)EC50 (µMol)11.10000.03002.27346.7000AID1721329
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (385)

Processvia Protein(s)Taxonomy
double-strand break repair via homologous recombination26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
double-strand break repair via nonhomologous end joining26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
ubiquitin-dependent protein catabolic process26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
response to ethanol26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
regulation of proteasomal protein catabolic process26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
protein K63-linked deubiquitination26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
protein deubiquitination26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
xenobiotic metabolic processCholinesteraseHomo sapiens (human)
learningCholinesteraseHomo sapiens (human)
negative regulation of cell population proliferationCholinesteraseHomo sapiens (human)
neuroblast differentiationCholinesteraseHomo sapiens (human)
peptide hormone processingCholinesteraseHomo sapiens (human)
response to alkaloidCholinesteraseHomo sapiens (human)
cocaine metabolic processCholinesteraseHomo sapiens (human)
negative regulation of synaptic transmissionCholinesteraseHomo sapiens (human)
response to glucocorticoidCholinesteraseHomo sapiens (human)
response to folic acidCholinesteraseHomo sapiens (human)
choline metabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic processCholinesteraseHomo sapiens (human)
angiogenesis72 kDa type IV collagenaseHomo sapiens (human)
ovarian follicle development72 kDa type IV collagenaseHomo sapiens (human)
ovulation from ovarian follicle72 kDa type IV collagenaseHomo sapiens (human)
luteinization72 kDa type IV collagenaseHomo sapiens (human)
blood vessel maturation72 kDa type IV collagenaseHomo sapiens (human)
intramembranous ossification72 kDa type IV collagenaseHomo sapiens (human)
proteolysis72 kDa type IV collagenaseHomo sapiens (human)
negative regulation of cell adhesion72 kDa type IV collagenaseHomo sapiens (human)
heart development72 kDa type IV collagenaseHomo sapiens (human)
embryo implantation72 kDa type IV collagenaseHomo sapiens (human)
parturition72 kDa type IV collagenaseHomo sapiens (human)
response to xenobiotic stimulus72 kDa type IV collagenaseHomo sapiens (human)
response to mechanical stimulus72 kDa type IV collagenaseHomo sapiens (human)
peripheral nervous system axon regeneration72 kDa type IV collagenaseHomo sapiens (human)
response to activity72 kDa type IV collagenaseHomo sapiens (human)
protein metabolic process72 kDa type IV collagenaseHomo sapiens (human)
extracellular matrix disassembly72 kDa type IV collagenaseHomo sapiens (human)
protein catabolic process72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of cell migration72 kDa type IV collagenaseHomo sapiens (human)
collagen catabolic process72 kDa type IV collagenaseHomo sapiens (human)
response to retinoic acid72 kDa type IV collagenaseHomo sapiens (human)
cellular response to reactive oxygen species72 kDa type IV collagenaseHomo sapiens (human)
response to nicotine72 kDa type IV collagenaseHomo sapiens (human)
endodermal cell differentiation72 kDa type IV collagenaseHomo sapiens (human)
response to hydrogen peroxide72 kDa type IV collagenaseHomo sapiens (human)
response to estrogen72 kDa type IV collagenaseHomo sapiens (human)
negative regulation of vasoconstriction72 kDa type IV collagenaseHomo sapiens (human)
ephrin receptor signaling pathway72 kDa type IV collagenaseHomo sapiens (human)
macrophage chemotaxis72 kDa type IV collagenaseHomo sapiens (human)
response to electrical stimulus72 kDa type IV collagenaseHomo sapiens (human)
response to hyperoxia72 kDa type IV collagenaseHomo sapiens (human)
face morphogenesis72 kDa type IV collagenaseHomo sapiens (human)
bone trabecula formation72 kDa type IV collagenaseHomo sapiens (human)
prostate gland epithelium morphogenesis72 kDa type IV collagenaseHomo sapiens (human)
cellular response to amino acid stimulus72 kDa type IV collagenaseHomo sapiens (human)
cellular response to interleukin-172 kDa type IV collagenaseHomo sapiens (human)
cellular response to estradiol stimulus72 kDa type IV collagenaseHomo sapiens (human)
cellular response to UV-A72 kDa type IV collagenaseHomo sapiens (human)
cellular response to fluid shear stress72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway72 kDa type IV collagenaseHomo sapiens (human)
response to amyloid-beta72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation72 kDa type IV collagenaseHomo sapiens (human)
extracellular matrix organization72 kDa type IV collagenaseHomo sapiens (human)
response to hypoxia72 kDa type IV collagenaseHomo sapiens (human)
tissue remodeling72 kDa type IV collagenaseHomo sapiens (human)
regulation of activated T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell tolerance inductionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of chronic inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of type 2 immune responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
female pregnancyIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic process to kynurenineIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
response to lipopolysaccharideIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of interleukin-10 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of interleukin-12 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
multicellular organismal response to stressIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
kynurenic acid biosynthetic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
swimming behaviorIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
'de novo' NAD biosynthetic process from tryptophanIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
behavioral fear responseCatechol O-methyltransferaseHomo sapiens (human)
response to hypoxiaCatechol O-methyltransferaseHomo sapiens (human)
synaptic transmission, dopaminergicCatechol O-methyltransferaseHomo sapiens (human)
startle responseCatechol O-methyltransferaseHomo sapiens (human)
response to amphetamineCatechol O-methyltransferaseHomo sapiens (human)
renin secretion into blood streamCatechol O-methyltransferaseHomo sapiens (human)
glycogen metabolic processCatechol O-methyltransferaseHomo sapiens (human)
prostaglandin metabolic processCatechol O-methyltransferaseHomo sapiens (human)
response to oxidative stressCatechol O-methyltransferaseHomo sapiens (human)
memoryCatechol O-methyltransferaseHomo sapiens (human)
visual learningCatechol O-methyltransferaseHomo sapiens (human)
response to xenobiotic stimulusCatechol O-methyltransferaseHomo sapiens (human)
response to woundingCatechol O-methyltransferaseHomo sapiens (human)
response to toxic substanceCatechol O-methyltransferaseHomo sapiens (human)
response to inorganic substanceCatechol O-methyltransferaseHomo sapiens (human)
gene expressionCatechol O-methyltransferaseHomo sapiens (human)
dopamine secretionCatechol O-methyltransferaseHomo sapiens (human)
cellular response to phosphate starvationCatechol O-methyltransferaseHomo sapiens (human)
cerebellar cortex morphogenesisCatechol O-methyltransferaseHomo sapiens (human)
response to foodCatechol O-methyltransferaseHomo sapiens (human)
methylationCatechol O-methyltransferaseHomo sapiens (human)
glomerulus developmentCatechol O-methyltransferaseHomo sapiens (human)
cholesterol effluxCatechol O-methyltransferaseHomo sapiens (human)
response to cytokineCatechol O-methyltransferaseHomo sapiens (human)
multicellular organism growthCatechol O-methyltransferaseHomo sapiens (human)
exploration behaviorCatechol O-methyltransferaseHomo sapiens (human)
renal sodium excretionCatechol O-methyltransferaseHomo sapiens (human)
norepinephrine metabolic processCatechol O-methyltransferaseHomo sapiens (human)
dopamine catabolic processCatechol O-methyltransferaseHomo sapiens (human)
catecholamine catabolic processCatechol O-methyltransferaseHomo sapiens (human)
habituationCatechol O-methyltransferaseHomo sapiens (human)
norepinephrine secretionCatechol O-methyltransferaseHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of painCatechol O-methyltransferaseHomo sapiens (human)
response to corticosteroneCatechol O-methyltransferaseHomo sapiens (human)
artery developmentCatechol O-methyltransferaseHomo sapiens (human)
cellular response to cocaineCatechol O-methyltransferaseHomo sapiens (human)
masticationCatechol O-methyltransferaseHomo sapiens (human)
renal albumin absorptionCatechol O-methyltransferaseHomo sapiens (human)
renal filtrationCatechol O-methyltransferaseHomo sapiens (human)
response to saltCatechol O-methyltransferaseHomo sapiens (human)
response to dopamineCatechol O-methyltransferaseHomo sapiens (human)
response to angiotensinCatechol O-methyltransferaseHomo sapiens (human)
dopamine metabolic processCatechol O-methyltransferaseHomo sapiens (human)
developmental processCatechol O-methyltransferaseHomo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
protein processingMethionine aminopeptidase 2Homo sapiens (human)
peptidyl-methionine modificationMethionine aminopeptidase 2Homo sapiens (human)
N-terminal protein amino acid modificationMethionine aminopeptidase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
regulation of translationMethionine aminopeptidase 1Homo sapiens (human)
proteolysisMethionine aminopeptidase 1Homo sapiens (human)
peptidyl-methionine modificationMethionine aminopeptidase 1Homo sapiens (human)
N-terminal protein amino acid modificationMethionine aminopeptidase 1Homo sapiens (human)
protein maturationMethionine aminopeptidase 1Homo sapiens (human)
platelet aggregationMethionine aminopeptidase 1Homo sapiens (human)
peptidyl-pyroglutamic acid biosynthetic process, using glutaminyl-peptide cyclotransferaseGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
protein modification processGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 8Homo sapiens (human)
chromatin organizationHistone deacetylase 8Homo sapiens (human)
mitotic sister chromatid cohesionHistone deacetylase 8Homo sapiens (human)
negative regulation of protein ubiquitinationHistone deacetylase 8Homo sapiens (human)
regulation of protein stabilityHistone deacetylase 8Homo sapiens (human)
regulation of telomere maintenanceHistone deacetylase 8Homo sapiens (human)
epigenetic regulation of gene expressionHistone deacetylase 8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (110)

Processvia Protein(s)Taxonomy
protein binding26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
metallopeptidase activity26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
metal ion binding26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
endopeptidase activator activity26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
K63-linked deubiquitinase activity26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
proteasome binding26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
metal-dependent deubiquitinase activity26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
amyloid-beta bindingCholinesteraseHomo sapiens (human)
catalytic activityCholinesteraseHomo sapiens (human)
acetylcholinesterase activityCholinesteraseHomo sapiens (human)
cholinesterase activityCholinesteraseHomo sapiens (human)
protein bindingCholinesteraseHomo sapiens (human)
hydrolase activity, acting on ester bondsCholinesteraseHomo sapiens (human)
enzyme bindingCholinesteraseHomo sapiens (human)
choline bindingCholinesteraseHomo sapiens (human)
identical protein bindingCholinesteraseHomo sapiens (human)
fibronectin binding72 kDa type IV collagenaseHomo sapiens (human)
endopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
metalloendopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
serine-type endopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
protein binding72 kDa type IV collagenaseHomo sapiens (human)
metallopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
zinc ion binding72 kDa type IV collagenaseHomo sapiens (human)
protein transmembrane transporter activityBotulinum neurotoxin type A Clostridium botulinum
electron transfer activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
heme bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
indoleamine 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
metal ion bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
magnesium ion bindingCatechol O-methyltransferaseHomo sapiens (human)
protein bindingCatechol O-methyltransferaseHomo sapiens (human)
methyltransferase activityCatechol O-methyltransferaseHomo sapiens (human)
O-methyltransferase activityCatechol O-methyltransferaseHomo sapiens (human)
catechol O-methyltransferase activityCatechol O-methyltransferaseHomo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
RNA bindingMethionine aminopeptidase 2Homo sapiens (human)
aminopeptidase activityMethionine aminopeptidase 2Homo sapiens (human)
initiator methionyl aminopeptidase activityMethionine aminopeptidase 2Homo sapiens (human)
protein bindingMethionine aminopeptidase 2Homo sapiens (human)
metalloexopeptidase activityMethionine aminopeptidase 2Homo sapiens (human)
metal ion bindingMethionine aminopeptidase 2Homo sapiens (human)
metalloaminopeptidase activityMethionine aminopeptidase 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
aminopeptidase activityMethionine aminopeptidase 1Homo sapiens (human)
initiator methionyl aminopeptidase activityMethionine aminopeptidase 1Homo sapiens (human)
protein bindingMethionine aminopeptidase 1Homo sapiens (human)
metalloexopeptidase activityMethionine aminopeptidase 1Homo sapiens (human)
metal ion bindingMethionine aminopeptidase 1Homo sapiens (human)
metalloaminopeptidase activityMethionine aminopeptidase 1Homo sapiens (human)
protein bindingGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
zinc ion bindingGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
glutaminyl-peptide cyclotransferase activityGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
histone deacetylase activityHistone deacetylase 8Homo sapiens (human)
protein bindingHistone deacetylase 8Homo sapiens (human)
Hsp70 protein bindingHistone deacetylase 8Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 8Homo sapiens (human)
metal ion bindingHistone deacetylase 8Homo sapiens (human)
Hsp90 protein bindingHistone deacetylase 8Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 8Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (77)

Processvia Protein(s)Taxonomy
proteasome complex26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
extracellular region26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
nucleus26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
nucleoplasm26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
cytosol26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
secretory granule lumen26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
ficolin-1-rich granule lumen26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
proteasome regulatory particle, lid subcomplex26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
proteasome accessory complex26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
cytosolic proteasome complex26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
nucleus26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
extracellular regionCholinesteraseHomo sapiens (human)
nuclear envelope lumenCholinesteraseHomo sapiens (human)
endoplasmic reticulum lumenCholinesteraseHomo sapiens (human)
blood microparticleCholinesteraseHomo sapiens (human)
plasma membraneCholinesteraseHomo sapiens (human)
extracellular spaceCholinesteraseHomo sapiens (human)
collagen-containing extracellular matrix72 kDa type IV collagenaseHomo sapiens (human)
extracellular region72 kDa type IV collagenaseHomo sapiens (human)
extracellular space72 kDa type IV collagenaseHomo sapiens (human)
nucleus72 kDa type IV collagenaseHomo sapiens (human)
mitochondrion72 kDa type IV collagenaseHomo sapiens (human)
plasma membrane72 kDa type IV collagenaseHomo sapiens (human)
sarcomere72 kDa type IV collagenaseHomo sapiens (human)
collagen-containing extracellular matrix72 kDa type IV collagenaseHomo sapiens (human)
extracellular space72 kDa type IV collagenaseHomo sapiens (human)
cytosolIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
smooth muscle contractile fiberIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
stereocilium bundleIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
cytoplasmIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
cytosolCatechol O-methyltransferaseHomo sapiens (human)
plasma membraneCatechol O-methyltransferaseHomo sapiens (human)
membraneCatechol O-methyltransferaseHomo sapiens (human)
intracellular membrane-bounded organelleCatechol O-methyltransferaseHomo sapiens (human)
synapseCatechol O-methyltransferaseHomo sapiens (human)
extracellular exosomeCatechol O-methyltransferaseHomo sapiens (human)
dendriteCatechol O-methyltransferaseHomo sapiens (human)
membraneCatechol O-methyltransferaseHomo sapiens (human)
axonCatechol O-methyltransferaseHomo sapiens (human)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
cytoplasmMethionine aminopeptidase 2Homo sapiens (human)
cytosolMethionine aminopeptidase 2Homo sapiens (human)
plasma membraneMethionine aminopeptidase 2Homo sapiens (human)
cytoplasmMethionine aminopeptidase 2Homo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
cytoplasmMethionine aminopeptidase 1Homo sapiens (human)
cytosolMethionine aminopeptidase 1Homo sapiens (human)
cytosolic ribosomeMethionine aminopeptidase 1Homo sapiens (human)
cytosolMethionine aminopeptidase 1Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
extracellular regionGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
specific granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
extracellular exosomeGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
tertiary granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
ficolin-1-rich granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
nuclear chromosomeHistone deacetylase 8Homo sapiens (human)
nucleusHistone deacetylase 8Homo sapiens (human)
nucleoplasmHistone deacetylase 8Homo sapiens (human)
cytoplasmHistone deacetylase 8Homo sapiens (human)
histone deacetylase complexHistone deacetylase 8Homo sapiens (human)
nucleusHistone deacetylase 8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (231)

Assay IDTitleYearJournalArticle
AID421776Upregulation of Rv3463 RNA expression in Mycobacterium tuberculosis H37Rv ATCC 27294 at 2 to 10 ug/ml after 6 hrs by microarray analysis2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Bioactive pyridine-N-oxide disulfides from Allium stipitatum.
AID637436Antioxidant activity assessed as AAPH-induced peroxyl radical scavenging activity at 1 mM by ORAC assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antioxidant properties of 4-quinolones and structurally related flavones.
AID1721328Substrate-dependent activation of HDAC8 (unknown origin) assessed as fold activation using FLUOR DE LYS as substrate at 20 uM incubated for 30 mins by fluorescence based assay relative to control2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
An in silico mechanistic insight into HDAC8 activation facilitates the discovery of new small-molecule activators.
AID1730328Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured after 48 hrs in presence of FeCl3 by MTT assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID96370Inhibit growth of KB cells by 50%1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Synthesis and antitumor activity of tropolone derivatives. 7. Bistropolones containing connecting methylene chains.
AID489472Inhibition of Staphylococcus aureus MetAP2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors.
AID1730309Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID489474Inhibition of human MetAP12010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors.
AID637441Antioxidant activity against toxin solution-induced lipid peroxidation in Sprague-Dawley rat brain homogenates assessed as free MDA levels per mg of tissue at 0.001 by TBARS assay (Rvb = 0.93 +/- 0.09 nmol)2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antioxidant properties of 4-quinolones and structurally related flavones.
AID276761Inhibition of PrP-res formation in mouse ScN2a cells relative to control2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Metal complexes with superoxide dismutase-like activity as candidates for anti-prion drug.
AID566702Inhibition of human recombinant MMP1 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID447578Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies.
AID421771Upregulation of sigH RNA expression in Mycobacterium tuberculosis H37Rv ATCC 27294 at 2 to 10 ug/ml after 6 hrs by microarray analysis2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Bioactive pyridine-N-oxide disulfides from Allium stipitatum.
AID1198409Anticandidal activity against Candida albicans ATCC 90028 incubated at 37 degC for 24 hrs by broth dilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds.
AID1911516Cytotoxicity against human MES-SA cells assessed as cell growth inhibition incubated for 72 hrs by PrestoBlue reagent based cell viability assay2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structure-Activity Relationships of 8-Hydroxyquinoline-Derived Mannich Bases with Tertiary Amines Targeting Multidrug-Resistant Cancer.
AID537733Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID421769Effect on trxC RNA expression in Mycobacterium tuberculosis H37Rv ATCC 27294 at 2 to 10 ug/ml after 6 hrs by microarray analysis2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Bioactive pyridine-N-oxide disulfides from Allium stipitatum.
AID1893771Inhibition of recombinant human QC using H-Gln-AMC hydrobromide as fluorogenic substrate incubated for 6 hrs by fluorometric microplate reader analysis2022ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
2-Amino-1,3,4-thiadiazoles as Glutaminyl Cyclases Inhibitors Increase Phagocytosis through Modification of CD47-SIRPα Checkpoint.
AID11369641-Octanol-water partition coefficient, log P of the compound by spectrophotometer analysis1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Quantitative structure-activity relationships for 5-substituted 8-hydroxyquinolines as inhibitors of dental plaque.
AID1911518Cytotoxicity against multidrug resistance human MES-SA/Dx5 cells assessed as cell growth inhibition incubated for 72 hrs by PrestoBlue reagent based cell viability assay2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structure-Activity Relationships of 8-Hydroxyquinoline-Derived Mannich Bases with Tertiary Amines Targeting Multidrug-Resistant Cancer.
AID1730323Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs in presence of FeCl3 by MTT assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID1730305Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability at 20 uM measured after 48 hrs by MTT assay relative to control2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID1148948Antibacterial activity against Streptococcus mutans 6715 assessed as inhibition of plaque formation in human teeth at 10'-2 M after 24 hrs1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Synthesis and in vitro evaluation of 8-hydroxyquinoline analogs as inhibitors of dental plaque.
AID1255355Ionophoric activity in human SH-SY5Y cells assessed as increase in cellular Zn uptake at 20 uM after 6 hrs by ICP-MS analysis relative to vehicle-treated control2015ACS medicinal chemistry letters, Sep-10, Volume: 6, Issue:9
Novel Fluorinated 8-Hydroxyquinoline Based Metal Ionophores for Exploring the Metal Hypothesis of Alzheimer's Disease.
AID566699Inhibition of mushroom tyrosinase at 1 mM after 10 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1339165Cytotoxicity against CD rat primary pulmonary vascular endothelial cells assessed as reduction in cell viability at 0.03 to 30 uM measured after 72 hrs by WST1 assay2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Rickettsia prowazekii methionine aminopeptidase as a promising target for the development of antibacterial agents.
AID346259Inhibition of Bacillus thermoproteolyticus thermolysin at 10 uM2009Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
Discovery of potent thermolysin inhibitors using structure based virtual screening and binding assays.
AID1730326Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability measured after 48 hrs in presence of FeCl3 by MTT assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID566704Inhibition of human recombinant MMP3 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1695875Antibacterial activity against Klebsiella pneumoniae ATCC 700603 incubated overnight by broth dilution technique2019European journal of medicinal chemistry, Apr-15, Volume: 168Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids.
AID694802Inhibition of Clostridium botulinum neurotoxin serotype A light chain at 500 uM2010ACS medicinal chemistry letters, , Volume: 1, Issue:6
Identification of a Natural Product Antagonist against the Botulinum Neurotoxin Light Chain Protease.
AID1136965Ionization constant, pKa of 8-hydroxyl group of the compound at 1 mM by potentiometric analysis1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Quantitative structure-activity relationships for 5-substituted 8-hydroxyquinolines as inhibitors of dental plaque.
AID1339159Antibacterial activity against Rickettsia prowazekii str. Breinl infected in CD rat primary pulmonary vascular endothelial cells assessed as protection against bacterial infection by measuring restoration of host cell viability at 0.03 to 30 uM measured 72017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Rickettsia prowazekii methionine aminopeptidase as a promising target for the development of antibacterial agents.
AID24630Compound was tested for their chelating potential with gallium-III complex determined by distribution coefficient method.1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis, physicochemical properties, and biological evaluation of hydroxypyranones and hydroxypyridinones: novel bidentate ligands for cell-labeling.
AID1136967Ionization constant, pKa of substituent at 5th position of the compound at 1 mM by potentiometric analysis1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Quantitative structure-activity relationships for 5-substituted 8-hydroxyquinolines as inhibitors of dental plaque.
AID1730325Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs in presence of FeCl3 by MTT assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID1182518Radioprotective activity against gamma-irradiated human MOLT4 cells preincubated for 1 hr at <50 uM before gamma-irradiation measured after 18 hrs by erythrosine B dye-exclusion test2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Design and synthesis of 8-hydroxyquinoline-based radioprotective agents.
AID1148946Antibacterial activity against Streptococcus mutans 6715 assessed as inhibition of plaque formation in human teeth at 10'-1 M after 24 hrs1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Synthesis and in vitro evaluation of 8-hydroxyquinoline analogs as inhibitors of dental plaque.
AID760045Inhibition of human methionine aminopeptidase 22013ACS medicinal chemistry letters, Jul-01, Volume: 4, Issue:8
Discovery of Inhibitors of
AID1480589Inhibition of 26S proteasome regulatory subunit RPN11 deubiquitinating activity in human erythrocytes using Ub4-pepOG protein substrate preincubated for 1 hr followed by substrate addition measured after 80 mins by fluorescence polarization assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Discovery of an Inhibitor of the Proteasome Subunit Rpn11.
AID1730308Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID346258Activity of Bacillus thermoproteolyticus thermolysin2009Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
Discovery of potent thermolysin inhibitors using structure based virtual screening and binding assays.
AID566701Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1695857Antibacterial activity against Enterococcus faecalis MTCC 439 incubated overnight by broth dilution technique2019European journal of medicinal chemistry, Apr-15, Volume: 168Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids.
AID1730307Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID1730315Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs in presence of CuCl2 by MTT assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID1304847Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate 2 incubated for 16 hrs by broth microdilution method in presence of tiron2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID421773Upregulation of dnaK RNA expression in Mycobacterium tuberculosis H37Rv ATCC 27294 at 2 to 10 ug/ml after 6 hrs by microarray analysis2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Bioactive pyridine-N-oxide disulfides from Allium stipitatum.
AID11369691-Octanol-water partition coefficient, log P of the compound by spectrophotometer analysis corrected for ionization1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Quantitative structure-activity relationships for 5-substituted 8-hydroxyquinolines as inhibitors of dental plaque.
AID1198426Toxicity in human RBC assessed as induction of hemolysis at 500 ug/ml incubated for 1 hr by spectrophotometry2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds.
AID1730310Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID1721329Substrate-dependent activation of HDAC8 (unknown origin) using FLUOR DE LYS as substrate incubated for 30 mins by fluorescence based assay2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
An in silico mechanistic insight into HDAC8 activation facilitates the discovery of new small-molecule activators.
AID1695856Antibacterial activity against Pseudomonas aeruginosa MTCC 2453 incubated overnight by broth dilution technique2019European journal of medicinal chemistry, Apr-15, Volume: 168Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids.
AID72038Ability to induce dNTP pool imbalance at 41 uM dose was tested; significant imbalance in the intracellular dNTP pool in FM3A cells1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Synthesis and antitumor activity of tropolone derivatives. 7. Bistropolones containing connecting methylene chains.
AID421770Upregulation of clpB RNA expression in Mycobacterium tuberculosis H37Rv ATCC 27294 at 2 to 10 ug/ml after 6 hrs by microarray analysis2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Bioactive pyridine-N-oxide disulfides from Allium stipitatum.
AID1304850Ratio of MIC for methicillin-resistant Staphylococcus aureus clinical isolate 2 in absence and presence of tiron2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID24629Compound was tested for their chelating potential with Iron-III complex determined by distribution coefficient method.1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis, physicochemical properties, and biological evaluation of hydroxypyranones and hydroxypyridinones: novel bidentate ligands for cell-labeling.
AID1198413Anticandidal activity against Candida tropicalis ATCC 750 incubated at 37 degC for 24 hrs by broth dilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds.
AID1730297Metal chelating activity assessed as compound-Fe3+ complex formation measured after 40 mins by calcein dye based fluorescence assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID1730327Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs in presence of FeCl3 by MTT assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID421778Upregulation of Rv1334 RNA expression in Mycobacterium tuberculosis H37Rv ATCC 27294 at 2 to 10 ug/ml after 6 hrs by microarray analysis2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Bioactive pyridine-N-oxide disulfides from Allium stipitatum.
AID421774Upregulation of hsp RNA expression in Mycobacterium tuberculosis H37Rv ATCC 27294 at 2 to 10 ug/ml after 6 hrs by microarray analysis2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Bioactive pyridine-N-oxide disulfides from Allium stipitatum.
AID1339155Inhibition of Rickettsia prowazekii str. Madrid E N-terminal His-tagged methionine aminopeptidase 1A expressed in Escherichia coli BL21(DE3) Rosetta cells using Met-AMC as substrate preincubated for 1 hr followed by substrate addition measured after 30 mi2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Rickettsia prowazekii methionine aminopeptidase as a promising target for the development of antibacterial agents.
AID1730318Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability measured after 48 hrs in presence of CuCl2 by MTT assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID1149251Inhibition of Sprague-Dawley rat liver COMT after 10 mins using 0.05 uCi [14CH3]-SAM as substrate1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Catechol O-methyltransferase. 8. Structure-activity relationships for inhibtion by 8-hydroxyquinolines.
AID760047Inhibition of Burkholderia pseudomallei recombinant methionine aminopeptidase 1 using H-Met-Gly-Pro-7-amino-4-methylcoumarin hydrochloride as substrate measured for 10 mins by fluorescence assay in presence of human recombinant DPP42013ACS medicinal chemistry letters, Jul-01, Volume: 4, Issue:8
Discovery of Inhibitors of
AID1148949Antibacterial activity against Streptococcus mutans 6715 assessed as inhibition of plaque formation in human teeth at 10'-2 M after 48 hrs1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Synthesis and in vitro evaluation of 8-hydroxyquinoline analogs as inhibitors of dental plaque.
AID643059Inhibition of human plasma lipoprotein-associated phospholipase A2 using 2-thio-PAF as substrate preincubated for 20 mins measured 1 hr post substrate addition by spectrophotometric analysis2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Amides of xanthurenic acid as zinc-dependent inhibitors of Lp-PLA(2).
AID1304851Ratio of MIC for methicillin-resistant Staphylococcus aureus clinical isolate 2 in absence and presence of Cu2+2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID1434686Inhibition of protease activity of recombinant full length Clostridium botulinum Hall BoNT/A light chain using SNAP-25 peptide (187 to 203 residues) as substrate after 5 mins by HPLC analysis2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
A matrix-focused structure-activity and binding site flexibility study of quinolinol inhibitors of botulinum neurotoxin serotype A.
AID1911520Selectivity ratio of IC50 for cytotoxicity against human MES-SA cells assessed as cell growth inhibition in presence of P-gp inhibitor Tariquidar to IC50 for cytotoxicity against multidrug resistance human MES-SA/Dx5 cells assessed as cell growth inhibiti2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structure-Activity Relationships of 8-Hydroxyquinoline-Derived Mannich Bases with Tertiary Amines Targeting Multidrug-Resistant Cancer.
AID1363208Inhibition of c-terminal hexa-His tagged human MB-COMT expressed in HEK293 cell membrane homogenate using norepinephrine as substrate after 1 hr in presence of SAM by MTase glo methyltransferase assay2018Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21
Optimization of 8-Hydroxyquinolines as Inhibitors of Catechol O-Methyltransferase.
AID1198411Anticandidal activity against Candida glabrata ATCC 90030 incubated at 37 degC for 24 hrs by broth dilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds.
AID491969Selectivity ratio of IC50 for bovine erythrocyte AChE to IC50 for human erythrocyte AChE2010Journal of medicinal chemistry, Jul-08, Volume: 53, Issue:13
Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties.
AID1911517Selectivity ratio of IC50 for cytotoxicity against human MES-SA cells assessed as cell growth inhibition to IC50 for cytotoxicity against multidrug resistance human MES-SA/Dx5 cells assessed as cell growth inhibition2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structure-Activity Relationships of 8-Hydroxyquinoline-Derived Mannich Bases with Tertiary Amines Targeting Multidrug-Resistant Cancer.
AID1304852Ratio of MIC for methicillin-resistant Staphylococcus aureus clinical isolate 2 in absence and presence of Fe2+2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID1339157Inhibition of recombinant full length human N-terminal GST/His6-tagged methionine aminopeptidase 2 expressed in baculovirus infected sf9 cells using methionylprolyl-p-nitroanilide as substrate preincubated for 20 mins followed by substrate addition measur2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Rickettsia prowazekii methionine aminopeptidase as a promising target for the development of antibacterial agents.
AID1198412Fungicidal activity against Candida glabrata ATCC 90030 incubated at 37 degC for 48 hrs by broth dilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds.
AID1730320Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured after 48 hrs in presence of CuCl2 by MTT assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID1480590Antiproliferative activity against human HCT116 cells after 72 hrs by Cell Titer-Glo assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Discovery of an Inhibitor of the Proteasome Subunit Rpn11.
AID489471Inhibition of Staphylococcus aureus MetAP at 25 uM2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors.
AID276766Cytotoxicity against prion Fukuoka1 strain infected mouse N2a#58 cells at 100 uM2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Metal complexes with superoxide dismutase-like activity as candidates for anti-prion drug.
AID1363242Inhibition of c-terminal hexa-His tagged human MB-COMT (unknown origin)2018Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21
Optimization of 8-Hydroxyquinolines as Inhibitors of Catechol O-Methyltransferase.
AID489470Inhibition of Escherichia coli MetAP2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors.
AID1730373Antitumor activity against human SW1990 cells xenografted in Balb/c nude mouse assessed as tumor growth inhibition at 20 mg/kg, iv administered every 3 days measured after 21 days relative to control2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID566703Inhibition of human recombinant MMP2 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1730319Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs in presence of CuCl2 by MTT assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID1695876Antibacterial activity against Escherichia coli ATCC 25922 incubated overnight by broth dilution technique2019European journal of medicinal chemistry, Apr-15, Volume: 168Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids.
AID566707Inhibition of mouse recombinant iNOS at 1 mM after 40 mins by colorimetric assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1730329Cytotoxicity against human SW1990 cells assessed as reduction in cell viability measured after 48 hrs in presence of FeCl3 by MTT assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID1530048Inhibition of Streptococcus pyogenes SrtA deltaN81 mutant expressed in Escherichia coli BL21(DE3) at 100 uM using Abz-LPETA-Dap(Dnp) as substrate preincubated for 10 mins followed by substrate addition measured every min for 2.5 hrs by fluorimetric assay 2019European journal of medicinal chemistry, Jan-01, Volume: 161Identification of potential antivirulence agents by substitution-oriented screening for inhibitors of Streptococcus pyogenes sortase A.
AID1730331Cytotoxicity against human RWPE2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID566708Inhibition of human recombinant MMP2 after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID276765Cytotoxicity against mouse ScN2a cells at 100 uM2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Metal complexes with superoxide dismutase-like activity as candidates for anti-prion drug.
AID24627Compound was tested for their chelating potential (free ligand) determined by distribution coefficient method.1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis, physicochemical properties, and biological evaluation of hydroxypyranones and hydroxypyridinones: novel bidentate ligands for cell-labeling.
AID421779Upregulation of Rv1335 RNA expression in Mycobacterium tuberculosis H37Rv ATCC 27294 at 2 to 10 ug/ml after 6 hrs by microarray analysis2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Bioactive pyridine-N-oxide disulfides from Allium stipitatum.
AID537736Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID1339170Antibacterial activity against Rickettsia prowazekii str. Breinl infected with 50:1 multiplicity of infection in CD rat primary pulmonary vascular endothelial cells assessed as restoration of host cell viability by measuring fold reduction in viability at2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Rickettsia prowazekii methionine aminopeptidase as a promising target for the development of antibacterial agents.
AID421768Effect on trxB2 RNA expression in Mycobacterium tuberculosis H37Rv ATCC 27294 at 2 to 10 ug/ml after 6 hrs by microarray analysis2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Bioactive pyridine-N-oxide disulfides from Allium stipitatum.
AID1911515Cytotoxicity against human MES-SA cells assessed as cell growth inhibition incubated for 72 hrs in presence of P-gp inhibitor Tariquidar by PrestoBlue reagent based cell viability assay2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structure-Activity Relationships of 8-Hydroxyquinoline-Derived Mannich Bases with Tertiary Amines Targeting Multidrug-Resistant Cancer.
AID1730317Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs in presence of CuCl2 by MTT assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID443993Inhibition of human recombinant IDO expressed in Escherichia coli BL21 AI2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Rational design of indoleamine 2,3-dioxygenase inhibitors.
AID72027Inhibit growth of FM3A cells by 50%1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Synthesis and antitumor activity of tropolone derivatives. 7. Bistropolones containing connecting methylene chains.
AID1730364Induction of apoptosis in human SW1990 cells at 12 uM measured after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID760043Antibacterial activity against Burkholderia thailandensis E264 assessed as bacterial growth inhibition at 1 mM after 24 hrs by two-fold dilution method relative to DMSO-treated control2013ACS medicinal chemistry letters, Jul-01, Volume: 4, Issue:8
Discovery of Inhibitors of
AID346257Inhibition of Bacillus thermoproteolyticus thermolysin2009Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
Discovery of potent thermolysin inhibitors using structure based virtual screening and binding assays.
AID1364303Antiparasitic activity against Toxoplasma gondii after 4 days by chlorophenol red-beta-D-galactosidase based assay2017Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7
Recent developments in drug discovery against the protozoal parasites Cryptosporidium and Toxoplasma.
AID694803Inhibition of Clostridium botulinum neurotoxin serotype A light chain preincubated for 5 mins before SNAPtid substrate addition by FRET assay2010ACS medicinal chemistry letters, , Volume: 1, Issue:6
Identification of a Natural Product Antagonist against the Botulinum Neurotoxin Light Chain Protease.
AID727214Cytotoxicity against human T47D cells at 50 ug/ml after 48 hrs by MTS assay relative to control2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Synthesis of 8-hydroxyquinoline derivatives as novel antitumor agents.
AID637438Antioxidant activity assessed as trolox equivalents ratio of ferric ion reducing activity using fe3+-TPTZ at 0.01 mM by FRAP assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antioxidant properties of 4-quinolones and structurally related flavones.
AID154261Tested in vivo for the antitumor activity against P388 in mice after intraperitoneal administration of 100 mg/kg dose; T/C= treated/control1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Synthesis and antitumor activity of tropolone derivatives. 7. Bistropolones containing connecting methylene chains.
AID283249Antimycobacterial activity against Mycobacterium tuberculosis H37Ra ATCC 25177 by microplate alamar blue assay2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
In vitro activities of cloxyquin (5-chloroquinolin-8-ol) against Mycobacterium tuberculosis.
AID1730312Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID1255354Ionophoric activity in human SH-SY5Y cells assessed as increase in cellular Cu uptake at 20 uM after 6 hrs by ICP-MS analysis relative to vehicle-treated control2015ACS medicinal chemistry letters, Sep-10, Volume: 6, Issue:9
Novel Fluorinated 8-Hydroxyquinoline Based Metal Ionophores for Exploring the Metal Hypothesis of Alzheimer's Disease.
AID1304854Aqueous solubility of compound in media after 16 hrs2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID1198415Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by neutral red assay2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds.
AID1628524Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by resazurin assay2016European journal of medicinal chemistry, Sep-14, Volume: 1208-Hydroxyquinolines in medicinal chemistry: A structural perspective.
AID489476Inhibition of human MetAP2 expressed in baculovirus infected Sf9 cells2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors.
AID1695858Antibacterial activity against Streptococcus pneumoniae MTCC 655 incubated overnight by broth dilution technique2019European journal of medicinal chemistry, Apr-15, Volume: 168Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids.
AID421777Upregulation of Rv3054c RNA expression in Mycobacterium tuberculosis H37Rv ATCC 27294 at 2 to 10 ug/ml after 6 hrs by microarray analysis2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Bioactive pyridine-N-oxide disulfides from Allium stipitatum.
AID637433Antioxidant activity assessed as trolox equivalents ratio of AAPH-induced peroxyl radical scavenging activity at 0.01 mM by ORAC assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antioxidant properties of 4-quinolones and structurally related flavones.
AID1706563Electrochemical behavior of the compound assessed as redox potential2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Hydroxypyridinone-Based Iron Chelators with Broad-Ranging Biological Activities.
AID760046Inhibition of human methionine aminopeptidase 12013ACS medicinal chemistry letters, Jul-01, Volume: 4, Issue:8
Discovery of Inhibitors of
AID1339156Inhibition of recombinant full length human His-tagged methionine aminopeptidase 1 expressed in Escherichia coli BL21(DE3) using methionylprolyl-p-nitroanilide as substrate preincubated for 20 mins followed by substrate addition measured for 20 mins in pr2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Rickettsia prowazekii methionine aminopeptidase as a promising target for the development of antibacterial agents.
AID1148947Antibacterial activity against Streptococcus mutans 6715 assessed as inhibition of plaque formation in human teeth at 10'-1 M after 48 hrs1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Synthesis and in vitro evaluation of 8-hydroxyquinoline analogs as inhibitors of dental plaque.
AID637437Antioxidant activity assessed as trolox equivalents ratio of ferric ion reducing activity using fe3+-TPTZ at 0.001 mM by FRAP assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antioxidant properties of 4-quinolones and structurally related flavones.
AID491968Antioxidant activity against AAPH-induced peroxyl radicals assessed as trolox equivalents measured for 80 mins by ORAC-FL method2010Journal of medicinal chemistry, Jul-08, Volume: 53, Issue:13
Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties.
AID1304849Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate 2 incubated for 16 hrs by broth microdilution method in presence of Fe2+2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID566700Inhibition of human recombinant 5-lipoxygenase at 1 mM after 10 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID489475Inhibition of human MetAP2 expressed in baculovirus infected Sf9 cells at 25 uM2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors.
AID1198410Fungicidal activity against Candida albicans ATCC 90028 incubated at 37 degC for 48 hrs by broth dilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds.
AID1911519Cytotoxicity against multidrug resistance human MES-SA/Dx5 cells assessed as cell growth inhibition incubated for 72 hrs in presence of P-gp inhibitor Tariquidar by PrestoBlue reagent based cell viability assay2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structure-Activity Relationships of 8-Hydroxyquinoline-Derived Mannich Bases with Tertiary Amines Targeting Multidrug-Resistant Cancer.
AID421775Upregulation of Rv0331 RNA expression in Mycobacterium tuberculosis H37Rv ATCC 27294 at 2 to 10 ug/ml after 6 hrs by microarray analysis2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Bioactive pyridine-N-oxide disulfides from Allium stipitatum.
AID537735Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID1730311Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID1198414Fungicidal activity against Candida tropicalis ATCC 750 incubated at 37 degC for 48 hrs by broth dilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds.
AID24628Compound was tested for their chelating potential with Indium-III complex determined by distribution coefficient method.1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis, physicochemical properties, and biological evaluation of hydroxypyranones and hydroxypyridinones: novel bidentate ligands for cell-labeling.
AID1198427Toxicity in human RBC assessed as induction of hemolysis at anticandidal IC50 level incubated for 1 hr by spectrophotometry2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds.
AID1068575Inhibition of Clostridium botulinum BoNT/A LC expressed in Escherichia coli assessed as cleavage of SNAPtide preincubated for 5 mins followed by SNAPtide addition measured for 105 mins by fluorescence assay2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Identification of clinically viable quinolinol inhibitors of botulinum neurotoxin A light chain.
AID566706Inhibition of human recombinant MMP9 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID537734Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID637444Antioxidant activity against toxin solution-induced lipid peroxidation in Sprague-Dawley rat brain homogenates assessed as free MDA levels per mg of tissue at 1 by TBARS assay (Rvb = 0.93 +/- 0.09 nmol)2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antioxidant properties of 4-quinolones and structurally related flavones.
AID489469Inhibition of Escherichia coli MetAP at 25 uM2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors.
AID170381Percentage of mobilization of iron in 2 hours from rat hepatocytes1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.
AID1730313Cytotoxicity against human SW1990 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID1136966Ionization constant, pKa of quinoline nitrogen group of the compound at 1 mM by potentiometric analysis1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Quantitative structure-activity relationships for 5-substituted 8-hydroxyquinolines as inhibitors of dental plaque.
AID727213Cytotoxicity against human K562 cells at 50 ug/ml after 48 hrs by MTS assay relative to control2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Synthesis of 8-hydroxyquinoline derivatives as novel antitumor agents.
AID643060Inhibition of human plasma lipoprotein-associated phospholipase A2 using 2-thio-PAF as substrate preincubated for 20 mins measured 1 hr post substrate addition by spectrophotometric analysis in presence of EDTA2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Amides of xanthurenic acid as zinc-dependent inhibitors of Lp-PLA(2).
AID1730322Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs in presence of FeCl3 by MTT assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID1304853Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate 2 incubated for 16 hrs by broth microdilution method2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID1406274Binding affinity to Cu2+ assessed as decrease in hydroxyl radical formation at 40 uM by CCA ascorbate assay2018European journal of medicinal chemistry, Aug-05, Volume: 156Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities.
AID1255356Ionophoric activity in human SH-SY5Y cells assessed as increase in cellular Fe uptake at 20 uM after 6 hrs by ICP-MS analysis relative to vehicle-treated control2015ACS medicinal chemistry letters, Sep-10, Volume: 6, Issue:9
Novel Fluorinated 8-Hydroxyquinoline Based Metal Ionophores for Exploring the Metal Hypothesis of Alzheimer's Disease.
AID154398Compound was tested in vivo for the antitumor activity against P388 leukemia cells in mice after intraperitoneal administration of 200 mg/kg dose; T/C= treated/control1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Synthesis and antitumor activity of tropolone derivatives. 7. Bistropolones containing connecting methylene chains.
AID1730321Cytotoxicity against human SW1990 cells assessed as reduction in cell viability measured after 48 hrs in presence of CuCl2 by MTT assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID491973Inhibition of human serum BChE by Ellman's reaction2010Journal of medicinal chemistry, Jul-08, Volume: 53, Issue:13
Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties.
AID491974Inhibition of human erythrocyte AChE by Ellman's reaction2010Journal of medicinal chemistry, Jul-08, Volume: 53, Issue:13
Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties.
AID11489451-Octanol-water partition coefficient, log P of the compound after 90 mins1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Synthesis and in vitro evaluation of 8-hydroxyquinoline analogs as inhibitors of dental plaque.
AID1730296Metal chelating activity assessed as compound-Cu2+ complex formation measured after 40 mins by calcein dye based fluorescence assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID1304861Dissociation constant, pKa of compound2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID28931Logarithm of cumulative stability constant was determined1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.
AID566705Inhibition of human recombinant MMP8 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID637435Antioxidant activity assessed as trolox equivalents ratio of AAPH-induced peroxyl radical scavenging activity at 0.1 mM by ORAC assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antioxidant properties of 4-quinolones and structurally related flavones.
AID100077Percentage of release of lactic dehydrogenase from rat hepatocytes1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.
AID1695855Antibacterial activity against Salmonella enterica MTCC 3224 incubated overnight by broth dilution technique2019European journal of medicinal chemistry, Apr-15, Volume: 168Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids.
AID421772Upregulation of dnaJ RNA expression in Mycobacterium tuberculosis H37Rv ATCC 27294 at 2 to 10 ug/ml after 6 hrs by microarray analysis2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Bioactive pyridine-N-oxide disulfides from Allium stipitatum.
AID637434Antioxidant activity assessed as trolox equivalents ratio of AAPH-induced peroxyl radical scavenging activity at 0.001 mM by ORAC assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antioxidant properties of 4-quinolones and structurally related flavones.
AID1730306Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID276762Inhibition of PrP-res formation in prion Fukuoka1 strain infected mouse N2a#58 cells relative to control2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Metal complexes with superoxide dismutase-like activity as candidates for anti-prion drug.
AID1730316Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs in presence of CuCl2 by MTT assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID637443Antioxidant activity against toxin solution-induced lipid peroxidation in Sprague-Dawley rat brain homogenates assessed as free MDA levels per mg of tissue at 0.1 by TBARS assay (Rvb = 0.93 +/- 0.09 nmol)2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antioxidant properties of 4-quinolones and structurally related flavones.
AID1304848Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate 2 incubated for 16 hrs by broth microdilution method in presence of Cu2+2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID637439Antioxidant activity assessed as trolox equivalents ratio of ferric ion reducing activity using fe3+-TPTZ at 0.1 mM by FRAP assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antioxidant properties of 4-quinolones and structurally related flavones.
AID1730324Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs in presence of FeCl3 by MTT assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID1730330Cytotoxicity against human H6C7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID1730372Antitumor activity against human SW1990 cells xenografted in Balb/c nude mouse assessed as tumor size at 20 mg/kg, iv administered every 3 days measured after 21 days (Rvb = 1.23 +/- 0.25 cm3)2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID637442Antioxidant activity against toxin solution-induced lipid peroxidation in Sprague-Dawley rat brain homogenates assessed as free MDA levels per mg of tissue at 0.01 by TBARS assay (Rvb = 0.93 +/- 0.09 nmol)2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antioxidant properties of 4-quinolones and structurally related flavones.
AID489473Inhibition of human MetAP1 at 25 uM2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors.
AID1730314Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs in presence of CuCl2 by MTT assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.
AID637440Antioxidant activity assessed as ferric ion reducing activity using fe3+-TPTZ at 1 mM by FRAP assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antioxidant properties of 4-quinolones and structurally related flavones.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1182520Cytotoxicity against human MOLT4 cells at 100 to 400 uM after 18 hrs by erythrosine B dye-exclusion test2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Design and synthesis of 8-hydroxyquinoline-based radioprotective agents.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2012Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry, Apr, Volume: 17, Issue:4
Potent inhibition of dinuclear zinc(II) peptidase, an aminopeptidase from Aeromonas proteolytica, by 8-quinolinol derivatives: inhibitor design based on Zn2+ fluorophores, kinetic, and X-ray crystallographic study.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,545)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990712 (46.08)18.7374
1990's211 (13.66)18.2507
2000's220 (14.24)29.6817
2010's294 (19.03)24.3611
2020's108 (6.99)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.57 (24.57)
Research Supply Index7.41 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index55.78 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials28 (1.73%)5.53%
Reviews53 (3.27%)6.00%
Case Studies91 (5.61%)4.05%
Observational1 (0.06%)0.25%
Other1,450 (89.34%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]